Lifeboat Foundation

Today we bring you an interview with Professor Steve Horvath pioneer of the epigenetic clocks of aging.

Steve Horvath is a Professor of Human Genetics and Biostatistics at UCLA. His research sits at the intersection of biostatistics, bioinformatics, computational biology, cancer research, genetics, epidemiology, epigenomics, machine learning, and systems biology.

In a paper published on March 15, 2018, in the journal Science, Stanford researchers led by Dr. Dena Leeman showed that intracellular protein aggregates accumulate within the lysosomes of neural stem cells that were previously thought not to suffer from this problem [1].

Intracellular waste disposal 101

Dysfunctional proteins and organelles within a cell constitute intracellular waste that the cell needs to dispose of. To do so, the cell may avail itself of proteasomes and lysosomes. Proteasomes are protein complexes that, with the help of enzymes, break down other, unnecessary proteins into shorter amino acids that can then be recycled to build new, useful proteins. Proteasomes are found within the cell nucleus and in the cytosol—the aqueous solution in which everything in a cell floats. The discovery of proteasomes happened later than that of lysosomes, which, for a while, were thought to be the only cellular waste management systems.

Continue reading “Clearing Protein Aggregates Boosts Neural Stem Cell Activity” »

The aging process is accompanied by a chronic, smoldering background of inflammation that researchers call “inflammaging”. This backdrop of low-grade inflammation contributes significantly to mortality risk in the elderly and has a number of sources.

Today, we are going to take a look at inflammaging and the various known sources that promote this age-related inflammatory condition.

Could advances in tech and medicine provide the key to finding solutions to some of humanity’s most devastating diseases?

A compound in beets that gives the vegetable its distinctive red color could eventually help slow the accumulation of misfolded proteins in the brain, a process that is associated with Alzheimer’s disease. Scientists say this discovery could lead to the development of drugs that could alleviate some of the long-term effects of the disease, the world’s leading cause of dementia.

A recent Stanford cancer study that cured 97 percent of mice from tumors has now moved on to soliciting human volunteers for a new cutting-edge medical trial.

The trial is part of a gathering wave of research into immunotherapy, a type of treatment that fights cancer by using the body’s immune system to attack tumors.

“Getting the immune system to fight cancer is one of the most recent developments in cancer,” Dr. Ronald Levy, a Stanford oncology professor who is leading the study, told SFGATE. “People need to know that this is in its early days and we are still looking for safety and looking to make this as good as it can be.”

Continue reading “Chemotherapy-free ‘cancer vaccine’ moves from mice to human trials at Stanford” »

A lzheimer’s sufferers could once again remember the faces of loved ones, or find their way back home, after scientists developed a way to boost memories.

In a groundbreaking pilot study, US researchers recorded memories as they were being formed and then later played them back into the brains of 10 patients.

They found that it increased memory performance by up to 37 per cent.

Continue reading “Alzheimer’s memories could be switched back on with implant” »

Research from Google Cloud finds that applying AI to medicine is tricky.

A class of antibiotics heralded as an essential future weapon against drug-resistant superbugs passed an important test. There’s now evidence that they can be used to treat serious infections in live animals (in vivo) without being toxic.

Researchers created simplified, synthetic versions of teixobactin, a protein produced by certain dirt-loving bacteria that was first discovered in 2015. They tested the teixobactin in lab mice whose eyes were infected with one of several germs, including antibiotic-resistant strains of Staphylococcus aureus and Enterococcus. The most successful of these analogues was found to leave animal cells alone while still wiping out more than 99 percent of the bacteria in the infected eye.

The findings were published in January in the Journal of Medicinal Chemistry.

Continue reading “An Experimental Superbug Killer Is a Tiny Step Closer to Saving Us From the Antibiotic Apocalypse” »